A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

860

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Chronic Lymphocytic LeukemiaWaldenstrom MacroglobulinemiaMantle Cell LymphomaMarginal Zone LymphomaB-cell LymphomaSmall Lymphocytic Lymphoma
Interventions
DRUG

Pirtobrutinib

Oral

DRUG

Venetoclax

Oral

DRUG

Rituximab

IV

Trial Locations (56)

3000

Peter MacCallum Cancer Centre, Melbourne

5042

Flinders Medical Centre, Bedford Park

6009

Linear Clinical Research, Nedlands

6500

Ospedale Regionale Bellinzona e Valli, Bellinzona

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

11042

Northwell Health, New Hyde Park

14263

Roswell Park Cancer Institute, Buffalo

19104

University of Pennsylvania Hospital, Philadelphia

20132

IRCCS Ospedale San Raffaele, Milan

27599

University of North Carolina at Chapel Hill, Chapel Hill

27705

Durham VA Medical Center, Durham

27710

Duke University Medical Center, Durham

30322

Emory Clinic, Atlanta

32224

Mayo Clinic-Jacksonville, Jacksonville

32746

Florida Cancer Specialists ORLANDO/DDU, Lake Mary

33136

Sylvester Comprehensive Cancer Center, Miami

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute SCRI, Nashville

40138

IRCCS - AOU di Bologna, Bologna

43210

Ohio State University Hospital, Columbus

44093

Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu, Nantes

44195

Cleveland Clinic Foundation, Cleveland

53226

Medical College of Wisconsin, Milwaukee

60611

Northwestern University, Chicago

66160

University of Kansas Medical Center, Kansas City

68105

University of Nebraska Medical Center, Omaha

75230

Mary Crowley Cancer Research Center, Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

84106

Utah Cancer Specialists, Salt Lake City

85259

Mayo Clinic of Scottsdale, Scottsdale

92103

Scripps Coastal Medical Center, San Diego

94117

University of California San Francisco, Medical Center at Paranassus, San Francisco

98104

Swedish Medical Center, Seattle

98195

Seattle Cancer Care Alliance, Seattle

06510

Smilow Cancer Hospital at Yale-New Haven, New Haven

02215

Dana-Farber Cancer Institute, Boston

55905-0002

Mayo Clinic, Rochester

460-0001

Nagoya Medical Center, Nagoya

060-8648

Hokkaido University Hospital, Sapporo

259-1193

Tokai University Hospital- Isehara Campus, Isehara

783-8505

Kochi Medical School Hospital, Nankoku

980-8574

Tohoku University Hospital, Sendai

104-0045

National Cancer Center Hospital, Chuo Ku

811-1395

National Hospital Organization Kyushu Cancer Center, Fukuoka

602-8566

Kyoto Furitsu Medical University Hospital, Kyoto

700-8558

Okayama University Hospital, Okayama

589-8511

Kindai University Hospital, Osakasayama-Shi

30-510

Pratia MCM Krakow, Krakow

Unknown

Instytut Hermatologii I Transfuzjologii, Warsaw

06351

Samsung Medical Center, Seoul

03080

Seoul National University Hospital, Seoul

171 65

Karolinska Institutet, Solna

LS9 7TF

St James's University Hospital, Leeds

OX3 7LJ

Churchill Hospital, Oxford

Pl6 8DH

Derriford Hospital, Plymouth

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Loxo Oncology, Inc.

INDUSTRY

NCT03740529 - A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Biotech Hunter | Biotech Hunter